ALMS – alumis inc. (US:NASDAQ)
Stock Stats
News
Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024
Alumis Inc. (NASDAQ: ALMS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Alumis Inc. (NASDAQ: ALMS) had its price target lowered by analysts at HC Wainwright from $30.00 to $26.00. They now have a "buy" rating on the stock.
Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements [Yahoo! Finance]
Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements
Form 10-Q ALUMIS INC. For: Sep 30
Form 8-K ALUMIS INC. For: Nov 13
Form SC 13D ALUMIS INC. Filed by: Samsara BioCapital, L.P.
Form 4/A ALUMIS INC. For: Jul 01 Filed by: AKKARAJU SRINIVAS
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.